Biodesix (NASDAQ:BDSX – Get Free Report) and First Choice Healthcare Solutions (OTCMKTS:FCHS – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends.
Volatility & Risk
Biodesix has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, First Choice Healthcare Solutions has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations for Biodesix and First Choice Healthcare Solutions, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Biodesix | 0 | 0 | 5 | 0 | 3.00 |
First Choice Healthcare Solutions | 0 | 0 | 0 | 0 | 0.00 |
Institutional and Insider Ownership
21.0% of Biodesix shares are owned by institutional investors. 69.2% of Biodesix shares are owned by company insiders. Comparatively, 30.8% of First Choice Healthcare Solutions shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Biodesix and First Choice Healthcare Solutions”s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Biodesix | $65.56 million | 1.96 | -$52.15 million | ($0.39) | -2.26 |
First Choice Healthcare Solutions | $30,000.00 | 7.36 | -$8.17 million | N/A | N/A |
First Choice Healthcare Solutions has lower revenue, but higher earnings than Biodesix.
Profitability
This table compares Biodesix and First Choice Healthcare Solutions’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Biodesix | -66.84% | -275.79% | -43.05% |
First Choice Healthcare Solutions | -9,943.78% | N/A | -123.38% |
Summary
Biodesix beats First Choice Healthcare Solutions on 9 of the 12 factors compared between the two stocks.
About Biodesix
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
About First Choice Healthcare Solutions
First Choice Healthcare Solutions, Inc. provides healthcare services in the United States. It develops primary care and wellness clinics focused on providing life improvement services, such as anti-aging, weight management, hormone replacement, and pharmacy services. The company is headquartered in Melbourne, Florida.
Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.